Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $32.60 Average Price Target from Analysts

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) has earned an average recommendation of “Hold” from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating and five have issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $32.60.

A number of research firms have issued reports on SLN. HC Wainwright reiterated a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Tuesday, September 16th. Chardan Capital reiterated a “buy” rating and set a $35.00 price target on shares of Silence Therapeutics in a report on Friday, August 8th. Wall Street Zen raised shares of Silence Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a research note on Wednesday, October 8th.

Silence Therapeutics Price Performance

Shares of NASDAQ:SLN opened at $6.58 on Tuesday. The firm has a fifty day moving average of $5.76 and a two-hundred day moving average of $5.45. Silence Therapeutics has a 12-month low of $1.97 and a 12-month high of $17.84.

Silence Therapeutics (NASDAQ:SLN) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.05). The company had revenue of $0.16 million during the quarter, compared to analyst estimates of $3.28 million. Silence Therapeutics had a negative return on equity of 56.38% and a negative net margin of 254.25%. On average, equities analysts predict that Silence Therapeutics will post -1.77 EPS for the current year.

Institutional Investors Weigh In On Silence Therapeutics

A number of hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC raised its holdings in shares of Silence Therapeutics by 134.1% in the 2nd quarter. GAMMA Investing LLC now owns 8,333 shares of the company’s stock valued at $48,000 after purchasing an additional 4,773 shares during the period. Beacon Pointe Advisors LLC acquired a new position in Silence Therapeutics during the second quarter worth approximately $67,000. Jump Financial LLC bought a new stake in Silence Therapeutics in the first quarter valued at approximately $74,000. Evelyn Partners Investment Management Services Ltd lifted its position in shares of Silence Therapeutics by 481.3% in the second quarter. Evelyn Partners Investment Management Services Ltd now owns 14,334 shares of the company’s stock valued at $77,000 after buying an additional 11,868 shares during the last quarter. Finally, Massar Capital Management LP bought a new position in shares of Silence Therapeutics during the 2nd quarter worth approximately $115,000. 98.73% of the stock is currently owned by institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.